How we evaluate peptide claims

Our rule: lead with the answer, link the evidence, and make uncertainty visible.

Evidence order

1. FDA labels, regulatory documents, and safety notices
2. Registered clinical trials and published human studies
3. Systematic reviews and professional guidelines
4. Animal and laboratory research, clearly labeled as preliminary

What every review must show

• What the evidence can and cannot establish
• Current U.S. regulatory status
• Important safety and quality gaps
• Source links and a last-reviewed date

Evidence grades

Established

Controlled human evidence and a defined medical use, usually with regulatory review.

Strong, specific

A credible result in a clearly defined population that should not be generalized beyond it.

Promising

A human signal exists, but study size, bias, duration, or replication limits confidence.

Not established

Human benefit has not been shown. Animal research, testimonials, or a trial registration are not counted as results.

What we refuse to do

We do not turn animal experiments into patient promises, describe a registered trial as a positive result, hide a manufacturer conflict, or imply that every product sharing a molecule name is equivalent to the material used in a study.

Commercial independence

We do not sell peptides or accept payment for favorable coverage. Market and laboratory-record data may be supplied by TitrateLab, and that relationship is disclosed.